[Never miss a great news story!', Get instant notifications from Economic Times', Allow', Not now', You can switch off notifications anytime using browser settings.', SECTIONS', ET APPS', ET Android App', ET iPhone App', ET iPad App', ET Wealth Android App', ET Blackberry App', ET Nokia App', ET Markets Android App', ET Markets iPhone App', ET Money Android App', ENGLISH', \u0939\u093f\u0928\u094d\u0926\u0940', \u0a97\u0ac1\u0a9c\u0ab0\u0abe\u0aa4\u0ac0', SIGN-IN', FOLLOW US', FACEBOOK', TWITTER', YOUTUBE', LINKEDIN', GOOGLE PLUS', RSS', Stock Price Quotes', LATEST NEWS', Mapping the market: Banks finally among gainers, but IT sours mood', Tech view: Nifty50 forms \u2018Long-legged Doji\u2019 pattern; 8,275 level key for bulls', Buy sectors that have growth at reasonable price: Anand Tandon', Oil hits 18-month highs as markets eye output cuts', Looking for a bullish upside at end of January: Sanjiv Bhasin, IIFL', Sensex, Nifty50 end marginally higher; Airtel falls 2%, PowerGrid gains 2%', 2 stocks that will help you make money: Avinnash Gorakssakar, Moneylicious', Infosys to announce Q3 earnings on January 13', Infosys to announce Q3 earnings on January 13', Home', Markets', News', Industry', Small Biz', Politics', Wealth', MF', Tech', Jobs', Opinion', Blogs', NRI', Magazines', Slideshows', ET NOW', ET Speed', ET Portfolio', Markets', Stocks', IPOs/FPOs', Market Stats', Market Moguls', Expert View', Technicals', Technical Chart', Visualize', Screener', Commodities', Views', News', Precious Metals', Gold Petal Delhi', Gold Petal', Silver Micro', Gold M', Gold', Silver M', Silver', Gold Guinea', Silver 1000', Others', Mentha Oil', Oil & Energy', Crude Oil Mini', Brent Crude Oil', Natural Gas', Crude Oil', Oil Seeds & Oils', Crude Palm Oil', Spices', Cardamom', Plantation', Kapas', Cotton', Base Metals', Lead Mini', Nickel Mini', Lead', Aluminium Mini', Aluminium', Nickel', Copper Mini', Copper', Zinc Mini', Zinc', Forex', Mobile Apps', ET Markets Android App', ET Markets iPhone App', More', Bonds', Stock Game', ChartMantra Technicals Trading Game', Webinars', Sitemap', Definitions', News', Live Blog', Trends', Recos', Earnings', ETMarkets Podcast', Market Paathshala', Announcements', Policy', Market Calendar', Stock Price Quotes', ET Home', \u203a', Markets', \u203a', Stocks', \u203a', Stock Price Quotes', \u203a', u"
		    var objPage = typeof objPage != 'undefined' ? objPage : {};
		    objPage.band_ad_active = '';
		    objPage.keepAdFirst = '';
		", 04:05 PM | 03 Jan', market stats', SENSEX', 26,643', 47.79', NIFTY 50', 8,192', 12.75', GOLD (MCX) (Rs/10g.)', 27,478', -92.00', USD/INR', 68.34', 0.11', Portfolio', Loading...', Select Portfolio and Asset Combination for Display on Market Band', Select Portfolio', Select Asset Class', Stocks', MF', ETF', Show More', CREATE PORTFOLIO', ADD INVESTMENT', 
                    	Download ET MARKETS APP
                    ', Get ET Markets in your own language', DOWNLOAD THE APP NOW', +91', CHOOSE LANGUAGE', ENG', ENG - English', HIN - \u0939\u093f\u0928\u094d\u0926\u0940', GUJ - \u0a97\u0ac1\u0a9c\u0ab0\u0abe\u0aa4\u0ac0', MAR - \u092e\u0930\u093e\u0920\u0940', BEN - \u09ac\u09be\u0982\u09b2\u09be ', KAN - \u0c95\u0ca8\u0ccd\u0ca8\u0ca1', ORI - \u0b13\u0b21\u0b3f\u0b06', TEL - \u0c24\u0c46\u0c32\u0c41\u0c17\u0c41', TAM - \u0ba4\u0bae\u0bbf\u0bb4\u0bcd', Sensex, Nifty50 rangebound; PowerGrid top gainer', Drag according to your convenience', ET NOW RADIO', ET NOW', TIMES NOW', u"var default_tv_popup = '';", Summary', Charts', News', Results', Returns', New', Compare ', Share Holding', Alembic Pharmaceuticals Ltd.', Add to Watchlist', |', Set Alerts', NSE', BSE', 602.00', 0.50',  ', (0.08%)', LIVE', 602.00', 2.50',  ', (0.42%)', LIVE', Volume', 36,777', 2,699', Mkt Cap (\u20b9 Cr.)', P/E (x)', Alembic Pharmaceuticals Ltd.', ET 500', Rank 2016', 319', ENG', New', ENG - English', HIN - \u0939\u093f\u0928\u094d\u0926\u0940', GUJ - \u0a97\u0ac1\u0a9c\u0ab0\u0abe\u0aa4\u0ac0', MAR - \u092e\u0930\u093e\u0920\u0940', BEN - \u09ac\u09be\u0982\u09b2\u09be ', KAN - \u0c95\u0ca8\u0ccd\u0ca8\u0ca1 ', ORI - \u0b13\u0b21\u0b3f\u0b06', TEL - \u0c24\u0c46\u0c32\u0c41\u0c17\u0c41', TAM - \u0ba4\u0bae\u0bbf\u0bb4\u0bcd', NSE', LIVE', BSE', LIVE', Add to Watchlist', |', Set Alerts', exchange = NSE, $nseExchange = NSE, $bseExchange = BSE, symbol = APLLTDEQ', 602.00', u"Today's Change", 0.50',  ', (0.08%)', Volume', AVERAGE VOLUME', 5-Day', 10-Day', 30-Day', 36,777', Open', 602.35', Prev. Close', 601.50', 602.00', u"Today's Change", 2.50',  ', (0.42%)', Volume', AVERAGE VOLUME', 5-Day', 10-Day', 30-Day', 2,699', Open', 603.10', Prev. Close', 599.50', u"Day's Trend", Bid', Mkt Cap (\u20b9 Cr.)', P/E (x)', P/B (x)', Div_ Yield (%)', BETA', BETA', 1 Month', 3-Months', 6-Months', 1 Year', 3-Years', Offer', Face Value (\u20b9)', EPS-TTM (Rs.)', BV/share (\u20b9)', 52Wk L/H', 512.50/ 699.00', Insights:', Events', |
											',  ', Recos', |
											', Updates', |
											', News', |
											', Speed', Technical Chart Provider : ', ChartIQ LLC', Alembic Pharmaceuticals Ltd Futures and Options Quotes', Instrument Type:', Futures', Options', Option Type:', Option Type', CE', PE', Expiry Date:', Expiry Date', Strike Price:', Strike Price',  ', Alembic Pharmaceuticals Ltd. News and Updates »', Alembic Pharmaceuticals receives USFDA Approval for Itraconazole Capsules', | Announcement', 16 Dec,2016, 10:31AM IST', Alembic Pharmaceuticals Ltd has informed BSE regarding a Press Release dated December 16, 2016 titled "Alembic Pharmaceuticals receives USFDA Approval for Itraconazole Capsules".', Alembic Pharmaceuticals Ltd has informed BSE regarding a Press Release dated December 16, 2016 titled "Alembic Pharmaceuticals receives USFDA Approval for Itraconazole Capsules".', less', Alembic Pharmaceuticals receives USFDA Approval for Zolmitriptan Orally Disintegrating Tablets', | Announcement', 05 Dec,2016, 10:19AM IST', Alembic Pharmaceuticals Ltd has submitted to BSE a copy of Press Release dated December 05, 2016 titled Alembic Pharmaceuticals receives USFDA Approval for Zolmitriptan Orally Disintegrating Tablets".', Alembic Pharmaceuticals Ltd has submitted to BSE a copy of Press Release dated December 05, 2016 titled Alembic Pharmaceuticals receives USFDA Approval for Zolmitriptan Orally Disintegrating Tablets".', less', Alembic Pharmaceuticals Limited receives USFDA Approval for Telmisartan and Amlodipine Tablets', | Announcement', 18 Nov,2016, 03:40PM IST', Alembic Pharmaceuticals Ltd has informed BSE regarding a Press Release dated November 18, 2016, title "Alembic Pharmaceuticals receives USFDA Approval for Telmisartan and Amlodipine Tablets".', Alembic Pharmaceuticals Ltd has informed BSE regarding a Press Release dated November 18, 2016, title "Alembic Pharmaceuticals receives USFDA Approval for Telmisartan and Amlodipine Tablets".', less', Alembic Pharma Q2 net dips 58% to Rs 119.83 cr', | Earnings', 25 Oct 2016, 04:36PM IST', The consolidated total income from operations also declined to Rs 879.42 crore for the quarter under consideration as ag... ', more', The consolidated total income from operations also declined to Rs 879.42 crore for the quarter under consideration as against Rs 1,018.07 crore for the same period year ago.', less', Outcome of Board Meeting', | Announcement', 25 Oct,2016, 02:14PM IST', Alembic Pharmaceuticals Ltd has informed BSE that the Board of Directors of the Company at its meeting held on October 25, 2016 has approved the reclassification of the status of certain shareholders from Promoter to Public category under Regulation 31A of SEBI (Listing Obligations and Disclosure Re... ', more', Alembic Pharmaceuticals Ltd has informed BSE that the Board of Directors of the Company at its meeting held on October 25, 2016 has approved the reclassification of the status of certain shareholders from Promoter to Public category under Regulation 31A of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015. The requisite application for stock exchange approval will be made in due course.', less', Announces Q2 Results (Standalone & Consolidated), Limited Review Report (Standalone & Consolidated), Results Press Relea...', | Announcement', 25 Oct,2016, 01:28PM IST', News Body Follows......', News Body Follows......', less', Disclosures under Reg. 10(6) of SEBI (SAST) Regulations, 2011', | Announcement', 21 Oct,2016, 02:04PM IST', Viramya Packlight Ltd has submitted the disclosures under Reg. 10(6) of SEBI (SAST) Regulations, 2011', Viramya Packlight Ltd has submitted the disclosures under Reg. 10(6) of SEBI (SAST) Regulations, 2011', less', Updates', | Announcement', 20 Oct,2016, 11:45AM IST', Alembic Pharmaceuticals Ltd has informed BSE that the Company has received request cum undertaking from the following persons to re-classify them from Promoter Category to Public Category pursuant to Regulation 31(A) of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015. 
 ... ', more', Alembic Pharmaceuticals Ltd has informed BSE that the Company has received request cum undertaking from the following persons to re-classify them from Promoter Category to Public Category pursuant to Regulation 31(A) of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015. 
 
 1. Ms. Jyoti Suresh Patel 
 
 2. Mr. Anup N Kothari 
 
 3. Ms. Ninochaka A Kothari 
 
 4. Ms. Shreya Rupendra Mukharji 
 
 5. Ms. Yeraben Ramanbhai Amin', less', Schedule of Post Results Conferece Call', | Announcement', 17 Oct,2016, 12:48AM IST', Alembic Pharmaceuticals Ltd has informed BSE regarding "Schedule of Post Results Conferece Call".', Alembic Pharmaceuticals Ltd has informed BSE regarding "Schedule of Post Results Conferece Call".', less', Disclosures under Reg. 10(5) in respect of acquisition under Reg. 10(1)(a) of SEBI (SAST) Regulations, 2011', | Announcement', 13 Oct,2016, 06:12PM IST', Viramya Packlight Ltd has submitted the disclosures under Reg. 10(5) in respect of acquisition under Reg. 10(1)(a) of SEBI (SAST) Reg. 2011', Viramya Packlight Ltd has submitted the disclosures under Reg. 10(5) in respect of acquisition under Reg. 10(1)(a) of SEBI (SAST) Reg. 2011', less', Updates', | Announcement', 05 Oct,2016, 11:18AM IST', Alembic Pharmaceuticals Ltd has informed BSE that the Companys Formulation Facility located at Panelav has received Establishment Inspection Report (EIR) from US Food & Drug Administration (FDA) for the inspection carried out by them in March, 2016.', Alembic Pharmaceuticals Ltd has informed BSE that the Companys Formulation Facility located at Panelav has received Establishment Inspection Report (EIR) from US Food & Drug Administration (FDA) for the inspection carried out by them in March, 2016.', less', Buy  Alembic Pharmaceuticals Ltd.  target Rs  728  :   Anand Rathi', | Recos', 04 Oct 2016, 02:04PM IST', The brokerage said the company is on track in terms of investment in R&D and capex for business growth', The brokerage said the company is on track in terms of investment in R&D and capex for business growth', less', Announces Q1 (Standalone & Consolidated) results, Limited Review Report (Standalone & Consolidated), Results Press Relea...', | Announcement', 29 Jul,2016, 01:28PM IST', News Body Follows......', News Body Follows......', less', Schedule of Post Results Conference Call', | Announcement', 21 Jul,2016, 11:14AM IST', Alembic Pharmaceuticals Ltd has informed BSE regarding "Schedule of Post Results Conference Call".', Alembic Pharmaceuticals Ltd has informed BSE regarding "Schedule of Post Results Conference Call".', less', Q1 results on July 29, 2016', | Announcement', 11 Jul,2016, 12:11AM IST', Alembic Pharmaceuticals Ltd has informed BSE that a meeting of the Board of Directors of the Company will be held on July 29, 2016, inter alia, to consider and approve the Unaudited Financial Results of the Company for the quarter ended on June 30, 2016 (Q1). 
 
 Further, the trading window shall re... ', more', Alembic Pharmaceuticals Ltd has informed BSE that a meeting of the Board of Directors of the Company will be held on July 29, 2016, inter alia, to consider and approve the Unaudited Financial Results of the Company for the quarter ended on June 30, 2016 (Q1). 
 
 Further, the trading window shall remain closed from July 26, 2016 to July 31, 2016 for the above purpose.', less', Mapping the market: Oil stocks slide, telecoms
out of coverage area', | News', 08 Jul 2016, 04:59PM IST', F&O turnover dropped, as was the activity in the cash market, as investors awaited fresh triggers in terms of earnings a... ', more', F&O turnover dropped, as was the activity in the cash market, as investors awaited fresh triggers in terms of earnings and progress of monsoon.', less', Updates', | Announcement', 08 Jul,2016, 01:01PM IST', Alembic Pharmaceuticals Ltd has informed BSE that the Company has received Establishment Inspection Report (EIR) from USFDA for the inspection carried out by them at the Companys Karakhadi API Plant III in April, 2015.', Alembic Pharmaceuticals Ltd has informed BSE that the Company has received Establishment Inspection Report (EIR) from USFDA for the inspection carried out by them at the Companys Karakhadi API Plant III in April, 2015.', less', Statement of Investor Complaint under Reg. 13(3) of SEBI (LODR) Regulations, 2015 for Quarter ended June 30, 2016', | Announcement', 08 Jul,2016, 12:10AM IST', Alembic Pharmaceuticals Ltd has informed BSE regarding Quarterly Statement on Investor Complaints / Grievances Redressal Mechanism for the Quarter ended June 30, 2016, under Regulation 13(3) of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015.', Alembic Pharmaceuticals Ltd has informed BSE regarding Quarterly Statement on Investor Complaints / Grievances Redressal Mechanism for the Quarter ended June 30, 2016, under Regulation 13(3) of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015.', less', Shareholding for the Period Ended June 30, 2016', | Announcement', 07 Jul,2016, 01:59PM IST', Alembic Pharmaceuticals Ltd has submitted to BSE the Shareholding Pattern for the Period Ended June 30, 2016. For more details, kindly ', Click here', Alembic Pharmaceuticals Ltd has submitted to BSE the Shareholding Pattern for the Period Ended June 30, 2016. For more details, kindly ', Click here', less', Alembic Pharmaceuticals receives USFDA Tentative Approval for Febuxostat Tablets', | Announcement', 05 Jul,2016, 10:27AM IST', Alembic Pharmaceuticals Ltd has informed BSE regarding a Press Release dated July 05, 2016 titled "Alembic Pharmaceuticals receives USFDA Tentative Approval for Febuxostat Tablets".', Alembic Pharmaceuticals Ltd has informed BSE regarding a Press Release dated July 05, 2016 titled "Alembic Pharmaceuticals receives USFDA Tentative Approval for Febuxostat Tablets".', less', (Alembic Pharmaceuticals Ltd. News, Recos, Events and Announcements)', 
    				    More', ET Buzz »', u"What's your view on Alembic Pharmaceuticals  for the week?", Bearish', Bullish', View community Outlook >>', Back', Community outlook on Alembic Pharmaceuticals  for the week.', Loading...', Post as Guest', New User? Join Now', We will never share or display your Email.', You will be notified, only if others like your post.', Post as Guest', Be the first one to post on Alembic Pharmaceuticals Ltd.', Alembic Pharmaceuticals Ltd.',  Quarterly Results', Yesconsolidate', Consolidate', Standalone', Loading...', Figures in Rs. Cr', Name', Sep 2016', % Chg',  (Quarterly)', % Chg',  (Yearly)', Peer Range', Trend', Last 12 Quarters Trend', Sales', 871.56', 19.88', -13.52', 0.00', 8265.12', Other Operating Income', 0.69', -31.68', -25.00', -0.01', 501.09', Operating Profit', 177.77', 13.26', -52.72', -55.64', 3780.39', Other Income', 0.50', 28.21', 900.00', -1.84', 119.40', EBITDA', 178.27', 13.30', -52.60', -55.64', 3780.39', Interest', 0.96', -10.28', 31.51', -2.65', 455.23', Depreciation', 20.62', 6.40', 55.39', 0.00', 303.83', Tax', 33.15', -0.36', -54.92', -57.96', 441.65', Net Profit', 119.83', 15.50', -58.52', -120.48', 2471.11', EPS', 6.36', 17.56', -58.49', -24.19', 84.57', View Detailed Financials:', Profit and Loss', Cash Flows', Balance Sheet', Quarterly Results', Half Year results', Capital Structure', Alembic Pharmaceuticals Ltd', Stock Performance', Financial performance', Vs peers', Companies', LTP', Intraday %', 1W %', 1M %', 1 QTR %', 1 YR %', 3 YR %', 5 Yr %', Trend -', D', |', M', |', Y', +', Alembic Pharma', 602.00', 0.08', -1.05', -4.47', -9.71', -13.51', 185.44', 1569.90', +', Pfizer', 1818.05', -0.56', 0.98', -3.72', -5.78', -22.92', 57.53', 65.43', +', Sanofi India', 4264.75', -0.72', 1.16', 0.70', 0.08', -2.60', 53.49', 85.16', +', Ipca Labs', 530.25', 0.13', 2.48', -6.16', -12.92', -28.53', -24.31', 87.67', +', Wockhardt', 666.35', -0.01', 4.02', -3.87', -25.63', -56.41', 50.77', 136.50', +', Strides Arcolab', 1048.50', -1.87', 0.50', -2.49', 2.99', -18.68', 186.87', 158.82', +', Abbott India', 4657.65', -1.24', 2.41', -4.39', -2.54', -22.51', 183.07', 221.06', 1', Jubilant Life', 638.00', 2.58', 10.08', -7.70', -2.49', 55.10', 394.00', 260.66', 1', Natco Pharma', 583.30', -0.22', -0.33', -0.84', -2.68', 0.69', 264.70', 1118.00', +', Shilpa Medicare', 705.95', 2.34', 4.93', 8.09', 17.59', 41.71', 421.84', 1152.80', +', Ajanta Pharma', 1797.35', -1.45', 3.56', -4.43', -14.13', 34.96', 380.68', 2115.67', Top Loser for the period amongst the peers', Top Gainer for the period amongst the peers', View Details:', Historical Prices', Dividends', Splits', Bonus', Rights', IPO Info', Alembic Pharmaceuticals Ltd Risk Return Comparison', with peers', New', Better performer than its peers on this ratio', Average performer than its peers on this ratio', Underperformer than its peers on this ratio', Alembic Pharmaceuticals Ltd Share Holding', Category', No. of shares', Percentage', Promoters', 140,162,135', 74.35', ForeignInstitutions', 20,558,956', 10.91', GeneralPublic', 18,751,627', 9.95', NBanksMutualFunds', 4,826,942', 2.56', Others', 3,612,865', 1.92', FinancialInstitutions', 603,389', 0.32', 
					            About Alembic Pharmaceuticals Ltd.', Alembic Pharmaceuticals Ltd., incorporated in the year 2010, is a Large Cap company (having a market cap of \u20b9 11301.53 Cr.) operating in Pharmaceuticals and health care sector. ', Alembic Pharmaceuticals Ltd. key Products/Revenue Segments include Tablets & Capsules which contributed \u20b9 1984.65 Cr to Sales Value (65.54 % of Total Sales), Bulk Drugs Intermediates And Chemicals which contributed \u20b9 507.46 Cr to Sales Value (16.76 % of Total Sales), Oral Preparations & Ointments which contributed \u20b9 369.55 Cr to Sales Value (12.20 % of Total Sales), Injectables which contributed \u20b9 79.21 Cr to Sales Value (2.61 % of Total Sales), Export Incentives which contributed \u20b9 57.42 Cr to Sales Value (1.89 % of Total Sales), Royalty Income which contributed \u20b9 25.97 Cr to Sales Value (0.85 % of Total Sales), Other Operating Revenue which contributed \u20b9 3.55 Cr to Sales Value (0.11 % of Total Sales)for the year ending 31-Mar-2016.', For the quarter ended 30-09-2016, the company has reported a  Consolidated sales of \u20b9 871.56 Cr., up 19.88 from last quarter Sales of \u20b9 727.02 Cr. and down -13.52 from last year same quarter Sales of \u20b9 1007.84 Cr. Company has reported net profit after tax of \u20b9 123.54 Cr. in latest quarter.', u"The company\u2019s CEO is Mr.Pranav Amin. It's Board of Directors include Mr.Ajay Desai, Dr.Archana Hingorani, Mr.Chirayu Amin, Mr.K G Ramanathan, Mr.Milin Mehta, Mr.Paresh Saraiya, Mr.Pranav Amin, Mr.Pranav Parikh, Mr.R K Baheti, Mr.Shaunak Amin, Mr.Ajay Desai. Company has its registered office at Alembic Road, Vadodra, 390003, Gujarat. Company has K S Aiyar & Co. as its auditors. As on 30-09-2016, the company has a total of 188,515,914 shares outstanding.", u"var dataArray = [['name','value'],
			['Promoters',140162135],['ForeignInstitutions',20558956],['GeneralPublic',18751627],['NBanksMutualFunds',4826942],['Others',3612865],['FinancialInstitutions',603389]];", View Details:', u"Chairman's Speech", Company History', Directors Report', Background information', Company Management', Listing Information', Finished Products', Board Meetings', AGM/EGM', Close X', Alert', Watchlist', Portfolio', Current Price: ', 2389.88', Lower Limit', Upper Limit', Set Alert', To continue receiving alerts, please enter your email id below:', Enter email address:', Submit', Add this company to your Watchlist', Select Watchlist', Create New WatchList', Add this company to your Portfolio', Select Portfolio', Create New Portfolio', Buy', Sell', BSE', NSE', Get Price', Quick Links', Alembic Pharmaceuticals .  Quick Links', Company Home', Cash Flow Statement', Half Yearly Results', Capital Structure', u"Chairman's Speech", Company History', Locations', Dividends', Splits', Competitors', Historical Prices', Balance Sheet', Nine Monthly Results', Shareholding Pattern', Finished Products', Background Information', Board Meetings', Bonus', IPO Information', Profit and Loss Account', Quarterly Results', Yearly Results', Directors Report', Company Management', Listing Information', AGM/EGM', Rights', News', Markets Quick Links', Daily Gainers', Most Active - Volume', NSE - All Indices', New 52Wk High', Near 52Wk High', Only Buyers', FII Activity', Weekly Gainers', Monthly Gainers', Sensex Constituents', u"Fall from Day's High", Daily Losers', Most Active - Value', Live Announcements', New 52Wk Low', Near 52Wk Low', Only Sellers', MF Activity', Weekly Losers', Monthly Losers', Nifty Constituents', u"Up from Day's Low", More from markets', ET Markets Home', Stocks Home', Market ', Live', IPO/FPO/Rights Issue', Views and Recommendations', Technical Charts', Portfolio', ET 500 Companies', Quarterly Results (Earnings)', View Complete Site Map  »', Date Sources:', Live BSE and NSE Quotes Service: TickerPlant | Corporate Data, F&O Data & Historical price volume data: Dion Global Solutions Ltd.', BSE Quotes and Sensex are real-time and licensed from the Bombay Stock Exchange. NSE Quotes and Nifty are also real time and licenced from National Stock Exchange. All times stamps are reflecting IST (Indian Standard Time).', By using this site, you agree to the Terms of Service and Privacy Policy.', Get a Quote', Browse Companies', A', B', C', D', E', F', G', H', I', J', K', L', M', N', O', P', Q', R', S', T', U', V', W', X', Y', Z', |', 1', 2', 3', 4', 5', 6', 7', 8', 9', Browse Mutual Funds', A', B', C', D', E', F', G', H', I', J', K', L', M', N', O', P', Q', R', S', T', U', V', W', X', Y', Z', The Economic Times', Live Market', News', Portfolio', Mobile', Live TV', Newsletter', Commodities', Speed', QnA', Blogs', Alerts', RSS', Other Times Group news sites', Times of India', |', \u0907\u0915\u0928\u0949\u092e\u093f\u0915 \u091f\u093e\u0907\u092e\u094d\u0938', \u0a88\u0a95\u0acb\u0aa8\u0acb\u0aae\u0abf\u0a95 \u0a9f\u0abe\u0a88\u0aae\u0acd\u0ab8', |', Mumbai Mirror', Times Now', |', Indiatimes', \u0928\u0935\u092d\u093e\u0930\u0924 \u091f\u093e\u0907\u092e\u094d\u0938', |', \u092e\u0939\u093e\u0930\u093e\u0937\u094d\u091f\u094d\u0930 \u091f\u093e\u0907\u092e\u094d\u0938', \u0cb5\u0cbf\u0c9c\u0caf \u0c95\u0cb0\u0ccd\u0ca8\u0cbe\u0c9f\u0c95', |', Lifehacker', Gizmodo', |', Eisamay', |', IGN India', NavGujarat Samay', Living and entertainment', Timescity', |', iDiva', |', Zoom', |', Luxpresso', |', Gaana', |', Happytrips', |', Cricbuzz', |', Get Smartapp', Networking', itimes', |', MensXP.com', Hot on the Web', Budget 2017', |', Sensex, Nifty Live', Year-End Special 2016', |', UP & Punjab Assembly Elections 2017', Live: Currency Demonetisation', |', Gold Rate', RBI Monetary Policy', Services', ads2book', |', Gadgetsnow', |', Free Business Listings', Simplymarry', |', Astrospeak', |', Timesjobs', |', Magicbricks', |', Zigwheels', |', Timesdeal', |', dineout', |', Filmipop', |', Remit2india', |', Gaana', |', Greetzap', |', Techradar', |', Alivear', |', Google Play',  | ', Manage Notifications', About us', /', Advertise with us', /', Terms of Use & Grievance Redressal', /', Privacy Policy', /', Feedback', /', Sitemap', /', Code of Ethics', /', /', Disclaimer', Copyright © 2016 Bennett, Coleman & Co. Ltd. All rights reserved.', 
                var _0x2144=["\x61\x64\x64\x45\x76\x65\x6E\x74\x4C\x69\x73\x74\x65\x6E\x65\x72","\x61\x74\x74\x61\x63\x68\x45\x76\x65\x6E\x74","\x72\x65\x6D\x6F\x76\x65\x45\x76\x65\x6E\x74\x4C\x69\x73\x74\x65\x6E\x65\x72","\x72\x65\x6D\x6F\x76\x65\x45\x76\x65\x6E\x74","\x63\x6F\x6E\x73\x6F\x6C\x65","\x65\x72\x72\x6F\x72","\x66\x6F\x72\x45\x61\x63\x68","\x73\x63\x72\x6F\x6C\x6C","\x63\x61\x6E\x52\x75\x6E","\x64\x65\x74\x65\x63\x74\x6F\x72","\x66\x75\x6E\x63\x74\x69\x6F\x6E","\x70\x75\x73\x68","\x68\x74\x74\x70\x3A\x2F\x2F\x73\x74\x61\x74\x69\x63\x2E\x63\x6C\x6D\x62\x74\x65\x63\x68\x2E\x63\x6F\x6D\x2F\x61\x73\x65\x2F\x32\x36\x35\x38\x2F\x33\x2F\x61\x61\x2E\x6A\x73","\x68\x74\x74\x70\x3A\x2F\x2F\x73\x74\x61\x74\x69\x63\x2E\x63\x6C\x6D\x62\x74\x65\x63\x68\x2E\x63\x6F\x6D\x2F\x61\x73\x65\x2F\x32\x33\x30\x38\x2F\x34\x2F\x61\x61\x2E\x6A\x73","\x68\x74\x74\x70\x3A\x2F\x2F\x70\x61\x72\x74\x6E\x65\x72\x2E\x67\x6F\x6F\x67\x6C\x65\x61\x64\x73\x65\x72\x76\x69\x63\x65\x73\x2E\x63\x6F\x6D\x2F\x67\x70\x74\x2F\x70\x75\x62\x61\x64\x73\x5F\x69\x6D\x70\x6C\x5F\x39\x32\x2E\x6A\x73","\x68\x74\x74\x70\x3A\x2F\x2F\x73\x74\x61\x74\x69\x63\x2E\x63\x68\x61\x72\x74\x62\x65\x61\x74\x2E\x63\x6F\x6D\x2F\x6A\x73\x2F\x63\x68\x61\x72\x74\x62\x65\x61\x74\x2E\x6A\x73","\x68\x74\x74\x70\x3A\x2F\x2F\x77\x77\x77\x2E\x67\x6F\x6F\x67\x6C\x65\x2D\x61\x6E\x61\x6C\x79\x74\x69\x63\x73\x2E\x63\x6F\x6D\x2F\x61\x6E\x61\x6C\x79\x74\x69\x63\x73\x2E\x6A\x73\x20","\x68\x74\x74\x70\x3A\x2F\x2F\x62\x2E\x73\x63\x6F\x72\x65\x63\x61\x72\x64\x72\x65\x73\x65\x61\x72\x63\x68\x2E\x63\x6F\x6D\x2F\x62\x65\x61\x63\x6F\x6E\x2E\x6A\x73\x20","\x68\x74\x74\x70\x3A\x2F\x2F\x74\x61\x67\x73\x2E\x63\x72\x77\x64\x63\x6E\x74\x72\x6C\x2E\x6E\x65\x74\x2F\x63\x2F\x32\x38\x30\x31\x2F\x63\x63\x2E\x6A\x73\x3F\x6E\x73\x3D\x5F\x63\x63\x32\x38\x30\x31","\x68\x74\x74\x70\x3A\x2F\x2F\x61\x64\x2E\x63\x72\x77\x64\x63\x6E\x74\x72\x6C\x2E\x6E\x65\x74\x2F\x35\x2F\x63\x3D\x32\x38\x30\x30\x2F\x70\x65\x3D\x79\x2F\x63\x61\x6C\x6C\x62\x61\x63\x6B\x3D\x63\x63\x75\x61\x64","\x68\x74\x74\x70\x3A\x2F\x2F\x73\x74\x61\x74\x69\x63\x2E\x63\x6C\x6D\x62\x74\x65\x63\x68\x2E\x63\x6F\x6D\x2F\x61\x64\x2F\x63\x6F\x6D\x6D\x6F\x6E\x73\x2F\x6A\x73\x2F\x63\x6F\x6C\x6F\x6D\x62\x69\x61\x5F\x76\x32\x2E\x6A\x73","\x68\x74\x74\x70\x3A\x2F\x2F\x66\x69\x6C\x65\x73\x2E\x61\x64\x73\x70\x64\x62\x6C\x2E\x63\x6F\x6D\x2F\x70\x75\x62\x6C\x69\x73\x68\x65\x72\x73\x2F\x74\x69\x6D\x65\x73\x6F\x66\x69\x6E\x64\x69\x61\x2F\x63\x6F\x64\x65\x2E\x6A\x73","\x68\x74\x74\x70\x3A\x2F\x2F\x61\x64\x73\x2E\x70\x75\x62\x6D\x61\x74\x69\x63\x2E\x63\x6F\x6D\x2F\x41\x64\x53\x65\x72\x76\x65\x72\x2F\x6A\x73\x2F\x70\x77\x74\x2F\x32\x33\x31\x30\x35\x2F\x34\x36\x2F\x70\x77\x74\x2E\x6A\x73","\x2A\x69\x6D\x61\x67\x65\x73\x2E\x74\x61\x62\x6F\x6F\x6C\x61\x2E\x63\x6F\x6D","\x2A\x61\x64\x73\x2E\x79\x61\x68\x6F\x6F\x2E\x63\x6F\x6D","\x44\x65\x62\x75\x67\x67\x69\x6E\x67\x20\x45\x72\x72\x6F\x72\x3A\x20","\x73\x72\x63","\x74\x61\x72\x67\x65\x74","\x6C\x6F\x67","\x6C\x65\x6E\x67\x74\x68","\x74\x61\x67\x4E\x61\x6D\x65","\x53\x43\x52\x49\x50\x54","\x49\x4D\x47","\x2A","\x73\x75\x62\x73\x74\x72","\x69\x6E\x64\x65\x78\x4F\x66","\x41\x64\x42\x6C\x6F\x63\x6B\x65\x72","\x41\x44\x42\x4C\x4F\x43\x4B\x45\x52\x4F\x4E","\x67\x61","\x73\x65\x6E\x64","\x65\x76\x65\x6E\x74","\x47\x41","\x75\x6E\x64\x65\x66\x69\x6E\x65\x64","\x2F\x62\x6C\x6F\x63\x6B\x65\x64\x2E\x63\x6D\x73","\x61\x72\x74\x69\x63\x6C\x65\x6C\x69\x73\x74\x5F\x65\x73\x69","\x70\x61\x74\x68\x6E\x61\x6D\x65","\x69\x73\x4C\x6F\x67\x67\x65\x64","\x73\x65\x74","\x64\x69\x6D\x65\x6E\x73\x69\x6F\x6E\x33","\x4C\x4F\x47\x47\x45\x44\x49\x4E","\x65\x74\x5F\x61\x64\x42\x6C\x6F\x63\x6B\x65\x64","\x6A\x53\x74\x6F\x72\x61\x67\x65","\x74\x69\x74\x6C\x65","\x68\x72\x65\x66","\x70\x75\x73\x68\x53\x74\x61\x74\x65","\x6C\x6F\x63\x61\x74\x69\x6F\x6E","\x67\x65\x74","\x64\x65\x6C\x65\x74\x65\x4B\x65\x79","\x41\x44\x42\x4C\x4F\x43\x4B\x45\x52\x4F\x46\x46","\x62\x61\x63\x6B"];(function(_0xe300x1,_0xe300x2){var _0xe300x3=[];function _0xe300x4(_0xe300x5,_0xe300x6){if(_0xe300x1[_0x2144[0]]){_0xe300x1[_0x2144[0]](_0xe300x5,_0xe300x6,false)}else {if(_0xe300x1[_0x2144[1]]){_0xe300x1[_0x2144[1]](_0xe300x5,_0xe300x6)}}}function _0xe300x7(_0xe300x5,_0xe300x6){if(_0xe300x1[_0x2144[2]]){_0xe300x1[_0x2144[2]](_0xe300x5,_0xe300x6)}else {if(_0xe300x1[_0x2144[3]]){_0xe300x1[_0x2144[3]](_0xe300x5,_0xe300x6)}}}function _0xe300x8(_0xe300x9){_0xe300x3[_0x2144[6]](function(_0xe300x6){try{_0xe300x6(_0xe300x9)}catch(e){if(_0xe300x2[_0x2144[4]]&& _0xe300x2[_0x2144[4]][_0x2144[5]]){_0xe300x2[_0x2144[4]][_0x2144[5]](e)}}})}function _0xe300xa(){_0xe300x7(_0x2144[7],_0xe300xa);_0xe300x8(true)}function _0xe300xb(){_0xe300x8(false)}if(!_0xe300x2[_0x2144[8]]){_0xe300x4(_0x2144[7],_0xe300xa)}else {setTimeout(_0xe300xb,100)};_0xe300x2[_0x2144[9]]= function(_0xe300xc){if(_0xe300xc&&  typeof _0xe300xc== _0x2144[10]){_0xe300x3[_0x2144[11]](_0xe300xc)}};if(_0xe300x1[_0x2144[0]]){var _0xe300xd=[_0x2144[12],_0x2144[13],_0x2144[14],_0x2144[15],_0x2144[16],_0x2144[17],_0x2144[18],_0x2144[19],_0x2144[20],_0x2144[21],_0x2144[22],_0x2144[23],_0x2144[24]];_0xe300x1[_0x2144[0]](_0x2144[5],function(_0xe300x5){console[_0x2144[28]](_0x2144[25]+ _0xe300x5[_0x2144[27]][_0x2144[26]]);for(var _0xe300xe=0;_0xe300xe< _0xe300xd[_0x2144[29]];_0xe300xe++){if(_0xe300x5&& _0xe300x5[_0x2144[27]]&& (_0xe300x5[_0x2144[27]][_0x2144[30]]== _0x2144[31]|| _0xe300x5[_0x2144[27]][_0x2144[30]]== _0x2144[32])&& _0xe300x5[_0x2144[27]][_0x2144[26]]&& (_0xe300x5[_0x2144[27]][_0x2144[26]]=== _0xe300xd[_0xe300xe]|| (_0xe300xd[_0xe300xe][0]== _0x2144[33]&& _0xe300x5[_0x2144[27]][_0x2144[26]][_0x2144[35]](_0xe300xd[_0xe300xe][_0x2144[34]](1))>  -1))){_0xe300x2[_0x2144[8]]= false}}},true)}}(document,window));(function(_0xe300x1,_0xe300x2){var _0xe300xf={GA:{CATEGORY:_0x2144[36],ACTION_DETECTED:_0x2144[37]}};function _0xe300x10(){if(_0xe300x2[_0x2144[38]]){ga(_0x2144[39],_0x2144[40],_0xe300xf[_0x2144[41]].CATEGORY,_0xe300xf[_0x2144[41]].ACTION_DETECTED)}}_0xe300x2[_0x2144[9]](function(_0xe300xa){if(_0xe300xa=== true&&  typeof blockedPage== _0x2144[42]&& _0xe300x2[_0x2144[38]]){ga(_0x2144[39],_0x2144[40],_0xe300xf[_0x2144[41]].CATEGORY,_0xe300xf[_0x2144[41]].ACTION_DETECTED)}})}(document,window));window[_0x2144[9]](function(_0xe300xa){var _0xe300x11=_0x2144[43];var _0xe300x12=(location[_0x2144[45]][_0x2144[35]](_0x2144[44]))?true:false;var _0xe300x13=( typeof redirectOff!= _0x2144[42]&& redirectOff== 1)?true:false;if(_0xe300xa=== true){if(location[_0x2144[45]]!= _0xe300x11&&  !(_0xe300x13)){if(( typeof _tp_data!= undefined)&& ( typeof _tp_data[_0x2144[46]]!= undefined)&& (_tp_data[_0x2144[46]]== true)){ga(_0x2144[47],_0x2144[48],_0x2144[49])};$[_0x2144[51]][_0x2144[47]](_0x2144[50],1);history[_0x2144[54]]({},document[_0x2144[52]],location[_0x2144[53]]);window[_0x2144[55]]= _0xe300x11}}else {var _0xe300x14=$[_0x2144[51]][_0x2144[56]](_0x2144[50]);if(_0xe300x14== 1&&  typeof blockedPage== _0x2144[42]){$[_0x2144[51]][_0x2144[57]](_0x2144[50]);ga(_0x2144[39],_0x2144[40],_0x2144[36],_0x2144[58])};if(location[_0x2144[45]]== _0xe300x11&&  !(history[_0x2144[29]]< 2)){history[_0x2144[59]]()}}})
            
			', 
				    var objLabels = {};
				    objLabels.getData = function (data) {
				        objLabels.data = data;
				    }
				',  objPage.language = "";var companytype = "", companyVal = '34421', companyNa = "Alembic Pharmaceuticals ", displayName = "",page = { compid : "34421", 
				compName : "Alembic Pharmaceuticals ",
		                        seo : "alembic-pharmaceuticals-ltd",
								scriptcode_bse : '',
								scriptcode_nse : '533573',
		                        sectionid : 1977021501
		                        };

					', var secname="Markets Stocks Stock Price Quotes";
		var agename='';', 
			var _sf_async_config = _sf_async_config || {uid:10538,domain:"economictimes.indiatimes.com"};
			_sf_async_config.sections = secname;
			_sf_async_config.authors = agename;
			(function(){
			  function loadChartbeat() {
			  	//alert(chartbeat);
			    window._sf_endpt=(new Date()).getTime();
			    var e = document.createElement('script');
			    e.setAttribute('language', 'javascript');
			    e.setAttribute('type', 'text/javascript');
			    e.setAttribute('src',
			       (("https:" == document.location.protocol) ? "https://s3.amazonaws.com/" : "http://") + "static.chartbeat.com/js/chartbeat.js");
			    document.body.appendChild(e);
			  }
			  var oldonload = window.onload;
			  window.onload = (typeof window.onload != 'function') ?
			     loadChartbeat : function() { oldonload(); loadChartbeat(); };
			})();
			
			', 
                     function invokeLogin(){							
						try{				
						isLoggedSso = getCookievaluetwitt('MSCSAuth');
						if(Get_Ckie('autologin')!=null){
							Delete_Ckie("autologin","/",".indiatimes.com");
						}
						tpbar1();
						}
						catch(ex)
						{					
						}					
					}
				   
				', var _mfq = _mfq || [];
    			    var mouseflowPath = '/stocks';
                    (function() {
                       var mf = document.createElement("script"); mf.type = "text/javascript"; mf.async = true;
                       mf.src = "//cdn.mouseflow.com/projects/81baae85-f91c-464e-ac38-15a987752b7a.js";
                       document.getElementsByTagName("head")[0].appendChild(mf);
                    })();', Loadingdata...', More on: ', Prices', | ', Financials',  | ', Company Info',  | ', Reports',  | ', News',  | ', Competitors', Add this company to WatchList', Select Watchlist', Create New WatchList', 
				    var companyid = '34421';
				    $(document).ready(function () {
    			        if($(window).width() > 1340) {
    			            loadjscssfile('/css_marketshome_v2.cms?v=4', 'css');
    			            //loadjscssfile('/js_marketshome_v1.cms', 'js');
    			        }
    			        
				        /*
				        setTimeout(function () {
				            loadjscssfile('http://platform.twitter.com/widgets.js', 'js');
				            loadjscssfile('https://apis.google.com/js/plusone.js', 'js');
				            loadjscssfile('//platform.linkedin.com/in.js', 'js');
				        }, 10000);
				        */
				    });
				    objBreakingNews.customRotationTime = 5000;
				    // objBreakingNews.pageTickerService = "/feed_stocks_breaking_news.cms?companyid=" + companyid + "&feedtype=json&callback=breakingnews";
				    objBreakingNews.pageTickerService = "/feed_marketslisting.cms?feedtype=json&msid=1977021501&curpg=1&callback=breakingnews";
				    ', #marketPageWidget .conatiner #news .category.hidden {  display: none;} #breakingNews a {text-decoration:none;}'][Never miss a great news story!', Get instant notifications from Economic Times', Allow', Not now', You can switch off notifications anytime using browser settings.', SECTIONS', ET APPS', ET Android App', ET iPhone App', ET iPad App', ET Wealth Android App', ET Blackberry App', ET Nokia App', ET Markets Android App', ET Markets iPhone App', ET Money Android App', ENGLISH', \u0939\u093f\u0928\u094d\u0926\u0940', \u0a97\u0ac1\u0a9c\u0ab0\u0abe\u0aa4\u0ac0', SIGN-IN', FOLLOW US', FACEBOOK', TWITTER', YOUTUBE', LINKEDIN', GOOGLE PLUS', RSS', Stock Price Quotes', LATEST NEWS', Mapping the market: Banks finally among gainers, but IT sours mood', Tech view: Nifty50 forms \u2018Long-legged Doji\u2019 pattern; 8,275 level key for bulls', Buy sectors that have growth at reasonable price: Anand Tandon', Oil hits 18-month highs as markets eye output cuts', Looking for a bullish upside at end of January: Sanjiv Bhasin, IIFL', Sensex, Nifty50 end marginally higher; Airtel falls 2%, PowerGrid gains 2%', 2 stocks that will help you make money: Avinnash Gorakssakar, Moneylicious', Infosys to announce Q3 earnings on January 13', Infosys to announce Q3 earnings on January 13', Home', Markets', News', Industry', Small Biz', Politics', Wealth', MF', Tech', Jobs', Opinion', Blogs', NRI', Magazines', Slideshows', ET NOW', ET Speed', ET Portfolio', Markets', Stocks', IPOs/FPOs', Market Stats', Market Moguls', Expert View', Technicals', Technical Chart', Visualize', Screener', Commodities', Views', News', Precious Metals', Gold Petal Delhi', Gold Petal', Silver Micro', Gold M', Gold', Silver M', Silver', Gold Guinea', Silver 1000', Others', Mentha Oil', Oil & Energy', Crude Oil Mini', Brent Crude Oil', Natural Gas', Crude Oil', Oil Seeds & Oils', Crude Palm Oil', Spices', Cardamom', Plantation', Kapas', Cotton', Base Metals', Lead Mini', Nickel Mini', Lead', Aluminium Mini', Aluminium', Nickel', Copper Mini', Copper', Zinc Mini', Zinc', Forex', Mobile Apps', ET Markets Android App', ET Markets iPhone App', More', Bonds', Stock Game', ChartMantra Technicals Trading Game', Webinars', Sitemap', Definitions', News', Live Blog', Trends', Recos', Earnings', ETMarkets Podcast', Market Paathshala', Announcements', Policy', Market Calendar', Stock Price Quotes', ET Home', \u203a', Markets', \u203a', Stocks', \u203a', Stock Price Quotes', \u203a', u"
		    var objPage = typeof objPage != 'undefined' ? objPage : {};
		    objPage.band_ad_active = '';
		    objPage.keepAdFirst = '';
		", 04:05 PM | 03 Jan', market stats', SENSEX', 26,643', 47.79', NIFTY 50', 8,192', 12.75', GOLD (MCX) (Rs/10g.)', 27,478', -92.00', USD/INR', 68.34', 0.11', Portfolio', Loading...', Select Portfolio and Asset Combination for Display on Market Band', Select Portfolio', Select Asset Class', Stocks', MF', ETF', Show More', CREATE PORTFOLIO', ADD INVESTMENT', 
                    	Download ET MARKETS APP
                    ', Get ET Markets in your own language', DOWNLOAD THE APP NOW', +91', CHOOSE LANGUAGE', ENG', ENG - English', HIN - \u0939\u093f\u0928\u094d\u0926\u0940', GUJ - \u0a97\u0ac1\u0a9c\u0ab0\u0abe\u0aa4\u0ac0', MAR - \u092e\u0930\u093e\u0920\u0940', BEN - \u09ac\u09be\u0982\u09b2\u09be ', KAN - \u0c95\u0ca8\u0ccd\u0ca8\u0ca1', ORI - \u0b13\u0b21\u0b3f\u0b06', TEL - \u0c24\u0c46\u0c32\u0c41\u0c17\u0c41', TAM - \u0ba4\u0bae\u0bbf\u0bb4\u0bcd', Sensex, Nifty50 rangebound; PowerGrid top gainer', Drag according to your convenience', ET NOW RADIO', ET NOW', TIMES NOW', u"var default_tv_popup = '';", Summary', Charts', News', Results', Returns', New', Compare ', Share Holding', Alembic Pharmaceuticals Ltd.', Add to Watchlist', |', Set Alerts', NSE', BSE', 602.00', 0.50',  ', (0.08%)', LIVE', 602.00', 2.50',  ', (0.42%)', LIVE', Volume', 36,777', 2,699', Mkt Cap (\u20b9 Cr.)', P/E (x)', Alembic Pharmaceuticals Ltd.', ET 500', Rank 2016', 319', ENG', New', ENG - English', HIN - \u0939\u093f\u0928\u094d\u0926\u0940', GUJ - \u0a97\u0ac1\u0a9c\u0ab0\u0abe\u0aa4\u0ac0', MAR - \u092e\u0930\u093e\u0920\u0940', BEN - \u09ac\u09be\u0982\u09b2\u09be ', KAN - \u0c95\u0ca8\u0ccd\u0ca8\u0ca1 ', ORI - \u0b13\u0b21\u0b3f\u0b06', TEL - \u0c24\u0c46\u0c32\u0c41\u0c17\u0c41', TAM - \u0ba4\u0bae\u0bbf\u0bb4\u0bcd', NSE', LIVE', BSE', LIVE', Add to Watchlist', |', Set Alerts', exchange = NSE, $nseExchange = NSE, $bseExchange = BSE, symbol = APLLTDEQ', 602.00', u"Today's Change", 0.50',  ', (0.08%)', Volume', AVERAGE VOLUME', 5-Day', 10-Day', 30-Day', 36,777', Open', 602.35', Prev. Close', 601.50', 602.00', u"Today's Change", 2.50',  ', (0.42%)', Volume', AVERAGE VOLUME', 5-Day', 10-Day', 30-Day', 2,699', Open', 603.10', Prev. Close', 599.50', u"Day's Trend", Bid', Mkt Cap (\u20b9 Cr.)', P/E (x)', P/B (x)', Div_ Yield (%)', BETA', BETA', 1 Month', 3-Months', 6-Months', 1 Year', 3-Years', Offer', Face Value (\u20b9)', EPS-TTM (Rs.)', BV/share (\u20b9)', 52Wk L/H', 512.50/ 699.00', Insights:', Events', |
											',  ', Recos', |
											', Updates', |
											', News', |
											', Speed', Technical Chart Provider : ', ChartIQ LLC', Alembic Pharmaceuticals Ltd Futures and Options Quotes', Instrument Type:', Futures', Options', Option Type:', Option Type', CE', PE', Expiry Date:', Expiry Date', Strike Price:', Strike Price',  ', Alembic Pharmaceuticals Ltd. News and Updates »', Alembic Pharmaceuticals receives USFDA Approval for Itraconazole Capsules', | Announcement', 16 Dec,2016, 10:31AM IST', Alembic Pharmaceuticals Ltd has informed BSE regarding a Press Release dated December 16, 2016 titled "Alembic Pharmaceuticals receives USFDA Approval for Itraconazole Capsules".', Alembic Pharmaceuticals Ltd has informed BSE regarding a Press Release dated December 16, 2016 titled "Alembic Pharmaceuticals receives USFDA Approval for Itraconazole Capsules".', less', Alembic Pharmaceuticals receives USFDA Approval for Zolmitriptan Orally Disintegrating Tablets', | Announcement', 05 Dec,2016, 10:19AM IST', Alembic Pharmaceuticals Ltd has submitted to BSE a copy of Press Release dated December 05, 2016 titled Alembic Pharmaceuticals receives USFDA Approval for Zolmitriptan Orally Disintegrating Tablets".', Alembic Pharmaceuticals Ltd has submitted to BSE a copy of Press Release dated December 05, 2016 titled Alembic Pharmaceuticals receives USFDA Approval for Zolmitriptan Orally Disintegrating Tablets".', less', Alembic Pharmaceuticals Limited receives USFDA Approval for Telmisartan and Amlodipine Tablets', | Announcement', 18 Nov,2016, 03:40PM IST', Alembic Pharmaceuticals Ltd has informed BSE regarding a Press Release dated November 18, 2016, title "Alembic Pharmaceuticals receives USFDA Approval for Telmisartan and Amlodipine Tablets".', Alembic Pharmaceuticals Ltd has informed BSE regarding a Press Release dated November 18, 2016, title "Alembic Pharmaceuticals receives USFDA Approval for Telmisartan and Amlodipine Tablets".', less', Alembic Pharma Q2 net dips 58% to Rs 119.83 cr', | Earnings', 25 Oct 2016, 04:36PM IST', The consolidated total income from operations also declined to Rs 879.42 crore for the quarter under consideration as ag... ', more', The consolidated total income from operations also declined to Rs 879.42 crore for the quarter under consideration as against Rs 1,018.07 crore for the same period year ago.', less', Outcome of Board Meeting', | Announcement', 25 Oct,2016, 02:14PM IST', Alembic Pharmaceuticals Ltd has informed BSE that the Board of Directors of the Company at its meeting held on October 25, 2016 has approved the reclassification of the status of certain shareholders from Promoter to Public category under Regulation 31A of SEBI (Listing Obligations and Disclosure Re... ', more', Alembic Pharmaceuticals Ltd has informed BSE that the Board of Directors of the Company at its meeting held on October 25, 2016 has approved the reclassification of the status of certain shareholders from Promoter to Public category under Regulation 31A of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015. The requisite application for stock exchange approval will be made in due course.', less', Announces Q2 Results (Standalone & Consolidated), Limited Review Report (Standalone & Consolidated), Results Press Relea...', | Announcement', 25 Oct,2016, 01:28PM IST', News Body Follows......', News Body Follows......', less', Disclosures under Reg. 10(6) of SEBI (SAST) Regulations, 2011', | Announcement', 21 Oct,2016, 02:04PM IST', Viramya Packlight Ltd has submitted the disclosures under Reg. 10(6) of SEBI (SAST) Regulations, 2011', Viramya Packlight Ltd has submitted the disclosures under Reg. 10(6) of SEBI (SAST) Regulations, 2011', less', Updates', | Announcement', 20 Oct,2016, 11:45AM IST', Alembic Pharmaceuticals Ltd has informed BSE that the Company has received request cum undertaking from the following persons to re-classify them from Promoter Category to Public Category pursuant to Regulation 31(A) of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015. 
 ... ', more', Alembic Pharmaceuticals Ltd has informed BSE that the Company has received request cum undertaking from the following persons to re-classify them from Promoter Category to Public Category pursuant to Regulation 31(A) of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015. 
 
 1. Ms. Jyoti Suresh Patel 
 
 2. Mr. Anup N Kothari 
 
 3. Ms. Ninochaka A Kothari 
 
 4. Ms. Shreya Rupendra Mukharji 
 
 5. Ms. Yeraben Ramanbhai Amin', less', Schedule of Post Results Conferece Call', | Announcement', 17 Oct,2016, 12:48AM IST', Alembic Pharmaceuticals Ltd has informed BSE regarding "Schedule of Post Results Conferece Call".', Alembic Pharmaceuticals Ltd has informed BSE regarding "Schedule of Post Results Conferece Call".', less', Disclosures under Reg. 10(5) in respect of acquisition under Reg. 10(1)(a) of SEBI (SAST) Regulations, 2011', | Announcement', 13 Oct,2016, 06:12PM IST', Viramya Packlight Ltd has submitted the disclosures under Reg. 10(5) in respect of acquisition under Reg. 10(1)(a) of SEBI (SAST) Reg. 2011', Viramya Packlight Ltd has submitted the disclosures under Reg. 10(5) in respect of acquisition under Reg. 10(1)(a) of SEBI (SAST) Reg. 2011', less', Updates', | Announcement', 05 Oct,2016, 11:18AM IST', Alembic Pharmaceuticals Ltd has informed BSE that the Companys Formulation Facility located at Panelav has received Establishment Inspection Report (EIR) from US Food & Drug Administration (FDA) for the inspection carried out by them in March, 2016.', Alembic Pharmaceuticals Ltd has informed BSE that the Companys Formulation Facility located at Panelav has received Establishment Inspection Report (EIR) from US Food & Drug Administration (FDA) for the inspection carried out by them in March, 2016.', less', Buy  Alembic Pharmaceuticals Ltd.  target Rs  728  :   Anand Rathi', | Recos', 04 Oct 2016, 02:04PM IST', The brokerage said the company is on track in terms of investment in R&D and capex for business growth', The brokerage said the company is on track in terms of investment in R&D and capex for business growth', less', Announces Q1 (Standalone & Consolidated) results, Limited Review Report (Standalone & Consolidated), Results Press Relea...', | Announcement', 29 Jul,2016, 01:28PM IST', News Body Follows......', News Body Follows......', less', Schedule of Post Results Conference Call', | Announcement', 21 Jul,2016, 11:14AM IST', Alembic Pharmaceuticals Ltd has informed BSE regarding "Schedule of Post Results Conference Call".', Alembic Pharmaceuticals Ltd has informed BSE regarding "Schedule of Post Results Conference Call".', less', Q1 results on July 29, 2016', | Announcement', 11 Jul,2016, 12:11AM IST', Alembic Pharmaceuticals Ltd has informed BSE that a meeting of the Board of Directors of the Company will be held on July 29, 2016, inter alia, to consider and approve the Unaudited Financial Results of the Company for the quarter ended on June 30, 2016 (Q1). 
 
 Further, the trading window shall re... ', more', Alembic Pharmaceuticals Ltd has informed BSE that a meeting of the Board of Directors of the Company will be held on July 29, 2016, inter alia, to consider and approve the Unaudited Financial Results of the Company for the quarter ended on June 30, 2016 (Q1). 
 
 Further, the trading window shall remain closed from July 26, 2016 to July 31, 2016 for the above purpose.', less', Mapping the market: Oil stocks slide, telecoms
out of coverage area', | News', 08 Jul 2016, 04:59PM IST', F&O turnover dropped, as was the activity in the cash market, as investors awaited fresh triggers in terms of earnings a... ', more', F&O turnover dropped, as was the activity in the cash market, as investors awaited fresh triggers in terms of earnings and progress of monsoon.', less', Updates', | Announcement', 08 Jul,2016, 01:01PM IST', Alembic Pharmaceuticals Ltd has informed BSE that the Company has received Establishment Inspection Report (EIR) from USFDA for the inspection carried out by them at the Companys Karakhadi API Plant III in April, 2015.', Alembic Pharmaceuticals Ltd has informed BSE that the Company has received Establishment Inspection Report (EIR) from USFDA for the inspection carried out by them at the Companys Karakhadi API Plant III in April, 2015.', less', Statement of Investor Complaint under Reg. 13(3) of SEBI (LODR) Regulations, 2015 for Quarter ended June 30, 2016', | Announcement', 08 Jul,2016, 12:10AM IST', Alembic Pharmaceuticals Ltd has informed BSE regarding Quarterly Statement on Investor Complaints / Grievances Redressal Mechanism for the Quarter ended June 30, 2016, under Regulation 13(3) of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015.', Alembic Pharmaceuticals Ltd has informed BSE regarding Quarterly Statement on Investor Complaints / Grievances Redressal Mechanism for the Quarter ended June 30, 2016, under Regulation 13(3) of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015.', less', Shareholding for the Period Ended June 30, 2016', | Announcement', 07 Jul,2016, 01:59PM IST', Alembic Pharmaceuticals Ltd has submitted to BSE the Shareholding Pattern for the Period Ended June 30, 2016. For more details, kindly ', Click here', Alembic Pharmaceuticals Ltd has submitted to BSE the Shareholding Pattern for the Period Ended June 30, 2016. For more details, kindly ', Click here', less', Alembic Pharmaceuticals receives USFDA Tentative Approval for Febuxostat Tablets', | Announcement', 05 Jul,2016, 10:27AM IST', Alembic Pharmaceuticals Ltd has informed BSE regarding a Press Release dated July 05, 2016 titled "Alembic Pharmaceuticals receives USFDA Tentative Approval for Febuxostat Tablets".', Alembic Pharmaceuticals Ltd has informed BSE regarding a Press Release dated July 05, 2016 titled "Alembic Pharmaceuticals receives USFDA Tentative Approval for Febuxostat Tablets".', less', (Alembic Pharmaceuticals Ltd. News, Recos, Events and Announcements)', 
    				    More', ET Buzz »', u"What's your view on Alembic Pharmaceuticals  for the week?", Bearish', Bullish', View community Outlook >>', Back', Community outlook on Alembic Pharmaceuticals  for the week.', Loading...', Post as Guest', New User? Join Now', We will never share or display your Email.', You will be notified, only if others like your post.', Post as Guest', Be the first one to post on Alembic Pharmaceuticals Ltd.', Alembic Pharmaceuticals Ltd.',  Quarterly Results', Yesconsolidate', Consolidate', Standalone', Loading...', Figures in Rs. Cr', Name', Sep 2016', % Chg',  (Quarterly)', % Chg',  (Yearly)', Peer Range', Trend', Last 12 Quarters Trend', Sales', 871.56', 19.88', -13.52', 0.00', 8265.12', Other Operating Income', 0.69', -31.68', -25.00', -0.01', 501.09', Operating Profit', 177.77', 13.26', -52.72', -55.64', 3780.39', Other Income', 0.50', 28.21', 900.00', -1.84', 119.40', EBITDA', 178.27', 13.30', -52.60', -55.64', 3780.39', Interest', 0.96', -10.28', 31.51', -2.65', 455.23', Depreciation', 20.62', 6.40', 55.39', 0.00', 303.83', Tax', 33.15', -0.36', -54.92', -57.96', 441.65', Net Profit', 119.83', 15.50', -58.52', -120.48', 2471.11', EPS', 6.36', 17.56', -58.49', -24.19', 84.57', View Detailed Financials:', Profit and Loss', Cash Flows', Balance Sheet', Quarterly Results', Half Year results', Capital Structure', Alembic Pharmaceuticals Ltd', Stock Performance', Financial performance', Vs peers', Companies', LTP', Intraday %', 1W %', 1M %', 1 QTR %', 1 YR %', 3 YR %', 5 Yr %', Trend -', D', |', M', |', Y', +', Alembic Pharma', 602.00', 0.08', -1.05', -4.47', -9.71', -13.51', 185.44', 1569.90', +', Pfizer', 1818.05', -0.56', 0.98', -3.72', -5.78', -22.92', 57.53', 65.43', +', Sanofi India', 4264.75', -0.72', 1.16', 0.70', 0.08', -2.60', 53.49', 85.16', +', Ipca Labs', 530.25', 0.13', 2.48', -6.16', -12.92', -28.53', -24.31', 87.67', +', Wockhardt', 666.35', -0.01', 4.02', -3.87', -25.63', -56.41', 50.77', 136.50', +', Strides Arcolab', 1048.50', -1.87', 0.50', -2.49', 2.99', -18.68', 186.87', 158.82', +', Abbott India', 4657.65', -1.24', 2.41', -4.39', -2.54', -22.51', 183.07', 221.06', 1', Jubilant Life', 638.00', 2.58', 10.08', -7.70', -2.49', 55.10', 394.00', 260.66', 1', Natco Pharma', 583.30', -0.22', -0.33', -0.84', -2.68', 0.69', 264.70', 1118.00', +', Shilpa Medicare', 705.95', 2.34', 4.93', 8.09', 17.59', 41.71', 421.84', 1152.80', +', Ajanta Pharma', 1797.35', -1.45', 3.56', -4.43', -14.13', 34.96', 380.68', 2115.67', Top Loser for the period amongst the peers', Top Gainer for the period amongst the peers', View Details:', Historical Prices', Dividends', Splits', Bonus', Rights', IPO Info', Alembic Pharmaceuticals Ltd Risk Return Comparison', with peers', New', Better performer than its peers on this ratio', Average performer than its peers on this ratio', Underperformer than its peers on this ratio', Alembic Pharmaceuticals Ltd Share Holding', Category', No. of shares', Percentage', Promoters', 140,162,135', 74.35', ForeignInstitutions', 20,558,956', 10.91', GeneralPublic', 18,751,627', 9.95', NBanksMutualFunds', 4,826,942', 2.56', Others', 3,612,865', 1.92', FinancialInstitutions', 603,389', 0.32', 
					            About Alembic Pharmaceuticals Ltd.', Alembic Pharmaceuticals Ltd., incorporated in the year 2010, is a Large Cap company (having a market cap of \u20b9 11301.53 Cr.) operating in Pharmaceuticals and health care sector. ', Alembic Pharmaceuticals Ltd. key Products/Revenue Segments include Tablets & Capsules which contributed \u20b9 1984.65 Cr to Sales Value (65.54 % of Total Sales), Bulk Drugs Intermediates And Chemicals which contributed \u20b9 507.46 Cr to Sales Value (16.76 % of Total Sales), Oral Preparations & Ointments which contributed \u20b9 369.55 Cr to Sales Value (12.20 % of Total Sales), Injectables which contributed \u20b9 79.21 Cr to Sales Value (2.61 % of Total Sales), Export Incentives which contributed \u20b9 57.42 Cr to Sales Value (1.89 % of Total Sales), Royalty Income which contributed \u20b9 25.97 Cr to Sales Value (0.85 % of Total Sales), Other Operating Revenue which contributed \u20b9 3.55 Cr to Sales Value (0.11 % of Total Sales)for the year ending 31-Mar-2016.', For the quarter ended 30-09-2016, the company has reported a  Consolidated sales of \u20b9 871.56 Cr., up 19.88 from last quarter Sales of \u20b9 727.02 Cr. and down -13.52 from last year same quarter Sales of \u20b9 1007.84 Cr. Company has reported net profit after tax of \u20b9 123.54 Cr. in latest quarter.', u"The company\u2019s CEO is Mr.Pranav Amin. It's Board of Directors include Mr.Ajay Desai, Dr.Archana Hingorani, Mr.Chirayu Amin, Mr.K G Ramanathan, Mr.Milin Mehta, Mr.Paresh Saraiya, Mr.Pranav Amin, Mr.Pranav Parikh, Mr.R K Baheti, Mr.Shaunak Amin, Mr.Ajay Desai. Company has its registered office at Alembic Road, Vadodra, 390003, Gujarat. Company has K S Aiyar & Co. as its auditors. As on 30-09-2016, the company has a total of 188,515,914 shares outstanding.", u"var dataArray = [['name','value'],
			['Promoters',140162135],['ForeignInstitutions',20558956],['GeneralPublic',18751627],['NBanksMutualFunds',4826942],['Others',3612865],['FinancialInstitutions',603389]];", View Details:', u"Chairman's Speech", Company History', Directors Report', Background information', Company Management', Listing Information', Finished Products', Board Meetings', AGM/EGM', Close X', Alert', Watchlist', Portfolio', Current Price: ', 2389.88', Lower Limit', Upper Limit', Set Alert', To continue receiving alerts, please enter your email id below:', Enter email address:', Submit', Add this company to your Watchlist', Select Watchlist', Create New WatchList', Add this company to your Portfolio', Select Portfolio', Create New Portfolio', Buy', Sell', BSE', NSE', Get Price', Quick Links', Alembic Pharmaceuticals .  Quick Links', Company Home', Cash Flow Statement', Half Yearly Results', Capital Structure', u"Chairman's Speech", Company History', Locations', Dividends', Splits', Competitors', Historical Prices', Balance Sheet', Nine Monthly Results', Shareholding Pattern', Finished Products', Background Information', Board Meetings', Bonus', IPO Information', Profit and Loss Account', Quarterly Results', Yearly Results', Directors Report', Company Management', Listing Information', AGM/EGM', Rights', News', Markets Quick Links', Daily Gainers', Most Active - Volume', NSE - All Indices', New 52Wk High', Near 52Wk High', Only Buyers', FII Activity', Weekly Gainers', Monthly Gainers', Sensex Constituents', u"Fall from Day's High", Daily Losers', Most Active - Value', Live Announcements', New 52Wk Low', Near 52Wk Low', Only Sellers', MF Activity', Weekly Losers', Monthly Losers', Nifty Constituents', u"Up from Day's Low", More from markets', ET Markets Home', Stocks Home', Market ', Live', IPO/FPO/Rights Issue', Views and Recommendations', Technical Charts', Portfolio', ET 500 Companies', Quarterly Results (Earnings)', View Complete Site Map  »', Date Sources:', Live BSE and NSE Quotes Service: TickerPlant | Corporate Data, F&O Data & Historical price volume data: Dion Global Solutions Ltd.', BSE Quotes and Sensex are real-time and licensed from the Bombay Stock Exchange. NSE Quotes and Nifty are also real time and licenced from National Stock Exchange. All times stamps are reflecting IST (Indian Standard Time).', By using this site, you agree to the Terms of Service and Privacy Policy.', Get a Quote', Browse Companies', A', B', C', D', E', F', G', H', I', J', K', L', M', N', O', P', Q', R', S', T', U', V', W', X', Y', Z', |', 1', 2', 3', 4', 5', 6', 7', 8', 9', Browse Mutual Funds', A', B', C', D', E', F', G', H', I', J', K', L', M', N', O', P', Q', R', S', T', U', V', W', X', Y', Z', The Economic Times', Live Market', News', Portfolio', Mobile', Live TV', Newsletter', Commodities', Speed', QnA', Blogs', Alerts', RSS', Other Times Group news sites', Times of India', |', \u0907\u0915\u0928\u0949\u092e\u093f\u0915 \u091f\u093e\u0907\u092e\u094d\u0938', \u0a88\u0a95\u0acb\u0aa8\u0acb\u0aae\u0abf\u0a95 \u0a9f\u0abe\u0a88\u0aae\u0acd\u0ab8', |', Mumbai Mirror', Times Now', |', Indiatimes', \u0928\u0935\u092d\u093e\u0930\u0924 \u091f\u093e\u0907\u092e\u094d\u0938', |', \u092e\u0939\u093e\u0930\u093e\u0937\u094d\u091f\u094d\u0930 \u091f\u093e\u0907\u092e\u094d\u0938', \u0cb5\u0cbf\u0c9c\u0caf \u0c95\u0cb0\u0ccd\u0ca8\u0cbe\u0c9f\u0c95', |', Lifehacker', Gizmodo', |', Eisamay', |', IGN India', NavGujarat Samay', Living and entertainment', Timescity', |', iDiva', |', Zoom', |', Luxpresso', |', Gaana', |', Happytrips', |', Cricbuzz', |', Get Smartapp', Networking', itimes', |', MensXP.com', Hot on the Web', Budget 2017', |', Sensex, Nifty Live', Year-End Special 2016', |', UP & Punjab Assembly Elections 2017', Live: Currency Demonetisation', |', Gold Rate', RBI Monetary Policy', Services', ads2book', |', Gadgetsnow', |', Free Business Listings', Simplymarry', |', Astrospeak', |', Timesjobs', |', Magicbricks', |', Zigwheels', |', Timesdeal', |', dineout', |', Filmipop', |', Remit2india', |', Gaana', |', Greetzap', |', Techradar', |', Alivear', |', Google Play',  | ', Manage Notifications', About us', /', Advertise with us', /', Terms of Use & Grievance Redressal', /', Privacy Policy', /', Feedback', /', Sitemap', /', Code of Ethics', /', /', Disclaimer', Copyright © 2016 Bennett, Coleman & Co. Ltd. All rights reserved.', 
                var _0x2144=["\x61\x64\x64\x45\x76\x65\x6E\x74\x4C\x69\x73\x74\x65\x6E\x65\x72","\x61\x74\x74\x61\x63\x68\x45\x76\x65\x6E\x74","\x72\x65\x6D\x6F\x76\x65\x45\x76\x65\x6E\x74\x4C\x69\x73\x74\x65\x6E\x65\x72","\x72\x65\x6D\x6F\x76\x65\x45\x76\x65\x6E\x74","\x63\x6F\x6E\x73\x6F\x6C\x65","\x65\x72\x72\x6F\x72","\x66\x6F\x72\x45\x61\x63\x68","\x73\x63\x72\x6F\x6C\x6C","\x63\x61\x6E\x52\x75\x6E","\x64\x65\x74\x65\x63\x74\x6F\x72","\x66\x75\x6E\x63\x74\x69\x6F\x6E","\x70\x75\x73\x68","\x68\x74\x74\x70\x3A\x2F\x2F\x73\x74\x61\x74\x69\x63\x2E\x63\x6C\x6D\x62\x74\x65\x63\x68\x2E\x63\x6F\x6D\x2F\x61\x73\x65\x2F\x32\x36\x35\x38\x2F\x33\x2F\x61\x61\x2E\x6A\x73","\x68\x74\x74\x70\x3A\x2F\x2F\x73\x74\x61\x74\x69\x63\x2E\x63\x6C\x6D\x62\x74\x65\x63\x68\x2E\x63\x6F\x6D\x2F\x61\x73\x65\x2F\x32\x33\x30\x38\x2F\x34\x2F\x61\x61\x2E\x6A\x73","\x68\x74\x74\x70\x3A\x2F\x2F\x70\x61\x72\x74\x6E\x65\x72\x2E\x67\x6F\x6F\x67\x6C\x65\x61\x64\x73\x65\x72\x76\x69\x63\x65\x73\x2E\x63\x6F\x6D\x2F\x67\x70\x74\x2F\x70\x75\x62\x61\x64\x73\x5F\x69\x6D\x70\x6C\x5F\x39\x32\x2E\x6A\x73","\x68\x74\x74\x70\x3A\x2F\x2F\x73\x74\x61\x74\x69\x63\x2E\x63\x68\x61\x72\x74\x62\x65\x61\x74\x2E\x63\x6F\x6D\x2F\x6A\x73\x2F\x63\x68\x61\x72\x74\x62\x65\x61\x74\x2E\x6A\x73","\x68\x74\x74\x70\x3A\x2F\x2F\x77\x77\x77\x2E\x67\x6F\x6F\x67\x6C\x65\x2D\x61\x6E\x61\x6C\x79\x74\x69\x63\x73\x2E\x63\x6F\x6D\x2F\x61\x6E\x61\x6C\x79\x74\x69\x63\x73\x2E\x6A\x73\x20","\x68\x74\x74\x70\x3A\x2F\x2F\x62\x2E\x73\x63\x6F\x72\x65\x63\x61\x72\x64\x72\x65\x73\x65\x61\x72\x63\x68\x2E\x63\x6F\x6D\x2F\x62\x65\x61\x63\x6F\x6E\x2E\x6A\x73\x20","\x68\x74\x74\x70\x3A\x2F\x2F\x74\x61\x67\x73\x2E\x63\x72\x77\x64\x63\x6E\x74\x72\x6C\x2E\x6E\x65\x74\x2F\x63\x2F\x32\x38\x30\x31\x2F\x63\x63\x2E\x6A\x73\x3F\x6E\x73\x3D\x5F\x63\x63\x32\x38\x30\x31","\x68\x74\x74\x70\x3A\x2F\x2F\x61\x64\x2E\x63\x72\x77\x64\x63\x6E\x74\x72\x6C\x2E\x6E\x65\x74\x2F\x35\x2F\x63\x3D\x32\x38\x30\x30\x2F\x70\x65\x3D\x79\x2F\x63\x61\x6C\x6C\x62\x61\x63\x6B\x3D\x63\x63\x75\x61\x64","\x68\x74\x74\x70\x3A\x2F\x2F\x73\x74\x61\x74\x69\x63\x2E\x63\x6C\x6D\x62\x74\x65\x63\x68\x2E\x63\x6F\x6D\x2F\x61\x64\x2F\x63\x6F\x6D\x6D\x6F\x6E\x73\x2F\x6A\x73\x2F\x63\x6F\x6C\x6F\x6D\x62\x69\x61\x5F\x76\x32\x2E\x6A\x73","\x68\x74\x74\x70\x3A\x2F\x2F\x66\x69\x6C\x65\x73\x2E\x61\x64\x73\x70\x64\x62\x6C\x2E\x63\x6F\x6D\x2F\x70\x75\x62\x6C\x69\x73\x68\x65\x72\x73\x2F\x74\x69\x6D\x65\x73\x6F\x66\x69\x6E\x64\x69\x61\x2F\x63\x6F\x64\x65\x2E\x6A\x73","\x68\x74\x74\x70\x3A\x2F\x2F\x61\x64\x73\x2E\x70\x75\x62\x6D\x61\x74\x69\x63\x2E\x63\x6F\x6D\x2F\x41\x64\x53\x65\x72\x76\x65\x72\x2F\x6A\x73\x2F\x70\x77\x74\x2F\x32\x33\x31\x30\x35\x2F\x34\x36\x2F\x70\x77\x74\x2E\x6A\x73","\x2A\x69\x6D\x61\x67\x65\x73\x2E\x74\x61\x62\x6F\x6F\x6C\x61\x2E\x63\x6F\x6D","\x2A\x61\x64\x73\x2E\x79\x61\x68\x6F\x6F\x2E\x63\x6F\x6D","\x44\x65\x62\x75\x67\x67\x69\x6E\x67\x20\x45\x72\x72\x6F\x72\x3A\x20","\x73\x72\x63","\x74\x61\x72\x67\x65\x74","\x6C\x6F\x67","\x6C\x65\x6E\x67\x74\x68","\x74\x61\x67\x4E\x61\x6D\x65","\x53\x43\x52\x49\x50\x54","\x49\x4D\x47","\x2A","\x73\x75\x62\x73\x74\x72","\x69\x6E\x64\x65\x78\x4F\x66","\x41\x64\x42\x6C\x6F\x63\x6B\x65\x72","\x41\x44\x42\x4C\x4F\x43\x4B\x45\x52\x4F\x4E","\x67\x61","\x73\x65\x6E\x64","\x65\x76\x65\x6E\x74","\x47\x41","\x75\x6E\x64\x65\x66\x69\x6E\x65\x64","\x2F\x62\x6C\x6F\x63\x6B\x65\x64\x2E\x63\x6D\x73","\x61\x72\x74\x69\x63\x6C\x65\x6C\x69\x73\x74\x5F\x65\x73\x69","\x70\x61\x74\x68\x6E\x61\x6D\x65","\x69\x73\x4C\x6F\x67\x67\x65\x64","\x73\x65\x74","\x64\x69\x6D\x65\x6E\x73\x69\x6F\x6E\x33","\x4C\x4F\x47\x47\x45\x44\x49\x4E","\x65\x74\x5F\x61\x64\x42\x6C\x6F\x63\x6B\x65\x64","\x6A\x53\x74\x6F\x72\x61\x67\x65","\x74\x69\x74\x6C\x65","\x68\x72\x65\x66","\x70\x75\x73\x68\x53\x74\x61\x74\x65","\x6C\x6F\x63\x61\x74\x69\x6F\x6E","\x67\x65\x74","\x64\x65\x6C\x65\x74\x65\x4B\x65\x79","\x41\x44\x42\x4C\x4F\x43\x4B\x45\x52\x4F\x46\x46","\x62\x61\x63\x6B"];(function(_0xe300x1,_0xe300x2){var _0xe300x3=[];function _0xe300x4(_0xe300x5,_0xe300x6){if(_0xe300x1[_0x2144[0]]){_0xe300x1[_0x2144[0]](_0xe300x5,_0xe300x6,false)}else {if(_0xe300x1[_0x2144[1]]){_0xe300x1[_0x2144[1]](_0xe300x5,_0xe300x6)}}}function _0xe300x7(_0xe300x5,_0xe300x6){if(_0xe300x1[_0x2144[2]]){_0xe300x1[_0x2144[2]](_0xe300x5,_0xe300x6)}else {if(_0xe300x1[_0x2144[3]]){_0xe300x1[_0x2144[3]](_0xe300x5,_0xe300x6)}}}function _0xe300x8(_0xe300x9){_0xe300x3[_0x2144[6]](function(_0xe300x6){try{_0xe300x6(_0xe300x9)}catch(e){if(_0xe300x2[_0x2144[4]]&& _0xe300x2[_0x2144[4]][_0x2144[5]]){_0xe300x2[_0x2144[4]][_0x2144[5]](e)}}})}function _0xe300xa(){_0xe300x7(_0x2144[7],_0xe300xa);_0xe300x8(true)}function _0xe300xb(){_0xe300x8(false)}if(!_0xe300x2[_0x2144[8]]){_0xe300x4(_0x2144[7],_0xe300xa)}else {setTimeout(_0xe300xb,100)};_0xe300x2[_0x2144[9]]= function(_0xe300xc){if(_0xe300xc&&  typeof _0xe300xc== _0x2144[10]){_0xe300x3[_0x2144[11]](_0xe300xc)}};if(_0xe300x1[_0x2144[0]]){var _0xe300xd=[_0x2144[12],_0x2144[13],_0x2144[14],_0x2144[15],_0x2144[16],_0x2144[17],_0x2144[18],_0x2144[19],_0x2144[20],_0x2144[21],_0x2144[22],_0x2144[23],_0x2144[24]];_0xe300x1[_0x2144[0]](_0x2144[5],function(_0xe300x5){console[_0x2144[28]](_0x2144[25]+ _0xe300x5[_0x2144[27]][_0x2144[26]]);for(var _0xe300xe=0;_0xe300xe< _0xe300xd[_0x2144[29]];_0xe300xe++){if(_0xe300x5&& _0xe300x5[_0x2144[27]]&& (_0xe300x5[_0x2144[27]][_0x2144[30]]== _0x2144[31]|| _0xe300x5[_0x2144[27]][_0x2144[30]]== _0x2144[32])&& _0xe300x5[_0x2144[27]][_0x2144[26]]&& (_0xe300x5[_0x2144[27]][_0x2144[26]]=== _0xe300xd[_0xe300xe]|| (_0xe300xd[_0xe300xe][0]== _0x2144[33]&& _0xe300x5[_0x2144[27]][_0x2144[26]][_0x2144[35]](_0xe300xd[_0xe300xe][_0x2144[34]](1))>  -1))){_0xe300x2[_0x2144[8]]= false}}},true)}}(document,window));(function(_0xe300x1,_0xe300x2){var _0xe300xf={GA:{CATEGORY:_0x2144[36],ACTION_DETECTED:_0x2144[37]}};function _0xe300x10(){if(_0xe300x2[_0x2144[38]]){ga(_0x2144[39],_0x2144[40],_0xe300xf[_0x2144[41]].CATEGORY,_0xe300xf[_0x2144[41]].ACTION_DETECTED)}}_0xe300x2[_0x2144[9]](function(_0xe300xa){if(_0xe300xa=== true&&  typeof blockedPage== _0x2144[42]&& _0xe300x2[_0x2144[38]]){ga(_0x2144[39],_0x2144[40],_0xe300xf[_0x2144[41]].CATEGORY,_0xe300xf[_0x2144[41]].ACTION_DETECTED)}})}(document,window));window[_0x2144[9]](function(_0xe300xa){var _0xe300x11=_0x2144[43];var _0xe300x12=(location[_0x2144[45]][_0x2144[35]](_0x2144[44]))?true:false;var _0xe300x13=( typeof redirectOff!= _0x2144[42]&& redirectOff== 1)?true:false;if(_0xe300xa=== true){if(location[_0x2144[45]]!= _0xe300x11&&  !(_0xe300x13)){if(( typeof _tp_data!= undefined)&& ( typeof _tp_data[_0x2144[46]]!= undefined)&& (_tp_data[_0x2144[46]]== true)){ga(_0x2144[47],_0x2144[48],_0x2144[49])};$[_0x2144[51]][_0x2144[47]](_0x2144[50],1);history[_0x2144[54]]({},document[_0x2144[52]],location[_0x2144[53]]);window[_0x2144[55]]= _0xe300x11}}else {var _0xe300x14=$[_0x2144[51]][_0x2144[56]](_0x2144[50]);if(_0xe300x14== 1&&  typeof blockedPage== _0x2144[42]){$[_0x2144[51]][_0x2144[57]](_0x2144[50]);ga(_0x2144[39],_0x2144[40],_0x2144[36],_0x2144[58])};if(location[_0x2144[45]]== _0xe300x11&&  !(history[_0x2144[29]]< 2)){history[_0x2144[59]]()}}})
            
			', 
				    var objLabels = {};
				    objLabels.getData = function (data) {
				        objLabels.data = data;
				    }
				',  objPage.language = "";var companytype = "", companyVal = '34421', companyNa = "Alembic Pharmaceuticals ", displayName = "",page = { compid : "34421", 
				compName : "Alembic Pharmaceuticals ",
		                        seo : "alembic-pharmaceuticals-ltd",
								scriptcode_bse : '',
								scriptcode_nse : '533573',
		                        sectionid : 1977021501
		                        };

					', var secname="Markets Stocks Stock Price Quotes";
		var agename='';', 
			var _sf_async_config = _sf_async_config || {uid:10538,domain:"economictimes.indiatimes.com"};
			_sf_async_config.sections = secname;
			_sf_async_config.authors = agename;
			(function(){
			  function loadChartbeat() {
			  	//alert(chartbeat);
			    window._sf_endpt=(new Date()).getTime();
			    var e = document.createElement('script');
			    e.setAttribute('language', 'javascript');
			    e.setAttribute('type', 'text/javascript');
			    e.setAttribute('src',
			       (("https:" == document.location.protocol) ? "https://s3.amazonaws.com/" : "http://") + "static.chartbeat.com/js/chartbeat.js");
			    document.body.appendChild(e);
			  }
			  var oldonload = window.onload;
			  window.onload = (typeof window.onload != 'function') ?
			     loadChartbeat : function() { oldonload(); loadChartbeat(); };
			})();
			
			', 
                     function invokeLogin(){							
						try{				
						isLoggedSso = getCookievaluetwitt('MSCSAuth');
						if(Get_Ckie('autologin')!=null){
							Delete_Ckie("autologin","/",".indiatimes.com");
						}
						tpbar1();
						}
						catch(ex)
						{					
						}					
					}
				   
				', var _mfq = _mfq || [];
    			    var mouseflowPath = '/stocks';
                    (function() {
                       var mf = document.createElement("script"); mf.type = "text/javascript"; mf.async = true;
                       mf.src = "//cdn.mouseflow.com/projects/81baae85-f91c-464e-ac38-15a987752b7a.js";
                       document.getElementsByTagName("head")[0].appendChild(mf);
                    })();', Loadingdata...', More on: ', Prices', | ', Financials',  | ', Company Info',  | ', Reports',  | ', News',  | ', Competitors', Add this company to WatchList', Select Watchlist', Create New WatchList', 
				    var companyid = '34421';
				    $(document).ready(function () {
    			        if($(window).width() > 1340) {
    			            loadjscssfile('/css_marketshome_v2.cms?v=4', 'css');
    			            //loadjscssfile('/js_marketshome_v1.cms', 'js');
    			        }
    			        
				        /*
				        setTimeout(function () {
				            loadjscssfile('http://platform.twitter.com/widgets.js', 'js');
				            loadjscssfile('https://apis.google.com/js/plusone.js', 'js');
				            loadjscssfile('//platform.linkedin.com/in.js', 'js');
				        }, 10000);
				        */
				    });
				    objBreakingNews.customRotationTime = 5000;
				    // objBreakingNews.pageTickerService = "/feed_stocks_breaking_news.cms?companyid=" + companyid + "&feedtype=json&callback=breakingnews";
				    objBreakingNews.pageTickerService = "/feed_marketslisting.cms?feedtype=json&msid=1977021501&curpg=1&callback=breakingnews";
				    ', #marketPageWidget .conatiner #news .category.hidden {  display: none;} #breakingNews a {text-decoration:none;}']